Jasinski Sylwia, Glasser Chana L
Department of Pediatric Hematology/Oncology, NYU Winthrop Hospital, Mineola, NY.
J Pediatr Hematol Oncol. 2019 Nov;41(8):624-626. doi: 10.1097/MPH.0000000000001307.
While packed red blood cell (PRBC) transfusion therapy is a mainstay in the treatment of certain patients with sickle cell disease (SCD) and the standard of care for preoperative management, there are associated risks. Delayed hemolytic transfusion reaction (DHTR) is a risk of PRBC transfusion occurring 2 to 20 days from transfusion and typically presents with severe pain characteristic of vaso-occlusive crisis, fever, and hemolytic anemia. DHTRs are uncommon, occurring in only 4% to 11% of transfused patients with SCD, but may be catastrophic in nature with progression to multiorgan failure within hours. Here, we describe a case of a 20-year-old female with sickle cell SS disease who developed a severe DHTR 5 days following an elective preoperative PRBC transfusion, and rapidly progressed to multiorgan failure and death. This is the first reported case of a catastrophic DHTR in a patient with SCD without any detectable known or new alloantibodies.
虽然浓缩红细胞(PRBC)输血疗法是治疗某些镰状细胞病(SCD)患者的主要手段以及术前管理的护理标准,但存在相关风险。迟发性溶血性输血反应(DHTR)是PRBC输血的一种风险,发生在输血后2至20天,通常表现为血管闭塞性危机的严重疼痛、发热和溶血性贫血。DHTR并不常见,仅发生在4%至11%的接受输血的SCD患者中,但可能具有灾难性,数小时内就会进展为多器官衰竭。在此,我们描述了一例20岁患有镰状细胞SS病的女性患者,在择期术前PRBC输血后5天发生严重DHTR,并迅速进展为多器官衰竭和死亡。这是首例报道的SCD患者发生灾难性DHTR且未检测到任何已知或新的同种抗体的病例。